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Glioblastoma (GBM) is the deadliest brain tumor. Its poor prognosis is due to
cell heterogeneity, invasiveness, and high vascularization that impede an efficient
therapeutic approach. In the past few years, several molecular links connecting GBM
to neurodegenerative diseases (NDDs) were identified at preclinical and clinical level.
In particular, giving the increasing critical role that epigenetic alterations play in both
GBM and NDDs, we deeply analyzed the role of miRNAs, small non-coding RNAs
acting epigenetic modulators in several key biological processes. Specific miRNAs,
transported by extracellular vesicles (EVs), act as intercellular communication signals
in both diseases. In this way, miRNA-loaded EVs modulate GBM tumorigenesis, as they
spread oncogenic signaling within brain parenchyma, and control the aggregation of
neurotoxic protein (Tau, Aβ-amyloid peptide, and α-synuclein) in NDDs. In this review,
we highlight the most promising miRNAs linking GBM and NDDs playing a significant
pathogenic role in both diseases.
Keywords: miRNAs, extracellular vesicles, glioblastoma, Alzheimer’s disease, Parkinson’s disease
Abbreviations: AD, Alzheimer’s disease; AKT2, RAC-beta serine/threonine-protein kinase; APP, amyloid precursor
protein; BBB, blood–brain barrier; CD, cluster of differentiation; CDC42, cell division control protein 42; CNS, central
nervous system; DNA, deoxyribonucleic acid; EMT, epithelial–mesenchymal transition; Epi-miRNA, epigenetic miRNA; EV,
extracellular vesicle; FOXO, forkhead box O; GBM, glioblastoma; GSCs, GBM stem cells; IDH, isocitrate dehydrogenase;
KANSL2, KAT8 Regulatory NSL Complex Subunit 2; MAPK, mitogen-activated protein kinase; NDDs, neurodegenerative
diseases; NSCs, neural stem cells; OCT4, octamer-binding transcription factor 4; OXR1, oxidation resistance 1; PD,
Parkinson’s disease; PDGFRA, platelet-derived growth factor receptor alpha; POUxFx, Pit-Oct-Unc Factor; RNA, ribonucleic
acid; SALL2, Spalt Like Transcription Factor 2; Sox, Sex determining Region Y-box; TMZ, Temozolomide; VFGF, vascular
endothelial growth factor; YBX1, Y-Box Binding Protein 1.
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INTRODUCTION
Glioblastoma recapitulates most of the hallmarks frequently
described in cancer, such as uncontrolled proliferation, apoptosis
resistance, dysregulated cell cycle, and angiogenesis. In contrast,
the opposite phenomena are described for NDDs as cell death
and tissue degeneration. Therefore, a contrasting nexus between
these illnesses can be inferred from this comparison. In support,
cancer and NDDs have shown inverse comorbidity (at least
for certain types of cancer), revealed by epidemiological studies
(Driver, 2014). Indeed, several proteins such as p53, cyclin
F, among others, were found to be inversely correlated in
NDD with cancer. In addition, several other factors were
up- or down-regulated in both diseases, including protein
phosphatase 2 (PP2A), cyclins D and E, among others (Seo
and Park, 2019). The existence of overlapping regulation of
pathogenic molecules involved in both GBM and NDDs,
although the underlying mechanisms of regulation could be
distinct, raise the possibility that these molecular links may
have the relevant potentiality to be exploited for developing
prognostic biomarkers and therapeutic strategies. Among
these linking molecules, both diseases closely associate with
miRNAs up- or down-regulation that modify protein expression
within the cells but can also be secreted to impact on
distant cell biology, making interesting to investigate their
correlations. This review analyses the biological significance of
the most dysregulated miRNAs detected in GBM as molecular
linkers to NDDs.
Glioblastoma
Glioblastoma is the deadliest and one of the more frequent CNS
tumor in adults. It has a poor prognosis due to its cellular
heterogeneity and complexity, the high local invasiveness and
the prominent neovascularization, which impede an efficient
therapeutic approach. Even when surgical removal could be
obtained, the tumor will most certainly relapse more aggressively,
and become lethal within a year. Furthermore, different
driver mutations would generate a particular microenvironment
affecting GBM (Chen and Hambardzumyan, 2018), with the
current cytotoxic therapies that also contribute to generate
additional mutations influencing the dynamic evolution of the
tumor growth and its heterogeneity (Sottoriva et al., 2013; Wang
et al., 2016; Garnier et al., 2018).
From a molecular point of view, GBM can be classified into
classical, mesenchymal, proneural, and neural subtypes (Verhaak
et al., 2010). The most prominent marker for each subtype is
EGFR, Neurofibromatosis type 1 (NF1), and PDGFRA/IDH1
genes, respectively (Verhaak et al., 2010; Galatro et al., 2017).
These tumors are vastly heterogeneous and therefore, they often
develop different mutations at the same time. In fact, the majority
of patients show areas characterizing different GBM subtypes
within the same tumor, with coexisting multiple tumor cell clones
presenting different genetic and epigenetic alterations (del Inda
et al., 2014; Teng et al., 2017; Neftel et al., 2019). Most of this
diversity is generated as a result of the interaction between tumor
cells and different environments during the growth of the tumor
(Sottoriva et al., 2013; Osuka and Van Meir, 2017).
Glioblastoma is enriched in stem-like tumor cells (GSCs)
(Persano et al., 2011). These cells can self-renew, and differentiate
into multiple cell types, increasing the dynamic of tumor
heterogeneity and resistance to drug and radiation (Chen et al.,
2012; Gimple et al., 2019). GSCs usually express markers, such
as CD133, a normal NSC marker in development, or CD44,
a progenitor cell marker, which interaction with hyaluronic
acid in extracellular matrix, favors GSC invasion of the brain
(Bradshaw et al., 2016). In this regard, CD133 or CD44
expression was proposed as a criterion for GBM classification:
CD133 is highly expressed in proneural GBMs and CD44
in mesenchymal GBM subtypes. Both markers are mutually
exclusive and independent of the stem cells’ properties within
the tumor (Brown et al., 2015). Also, GSCs express stem cell
transcription factors including NANOG, SOX2, POU1F5/OCT4,
c-Myc, KANSL2, POU3F2, SALL2 among others, which are
involved in proliferation and pluripotency maintenance (Suvà
et al., 2014; Ferreyra Solari et al., 2016).
The surroundings where GSCs home are called tumor niches
and consist of heterogeneous microenvironments. They differ
from the intratumor heterogeneity derived from diverse cell
types and mutations. Particularly, these niches contain tumor-
associated microglia/macrophages (TAMs) (Sørensen et al.,
2018), which can exhibit a wide range of functional properties,
displaying characteristics of either M1 or M2 microglia (in the
M1/M2 model), but also in between, hence this model becomes
rather too simplistic for describing TAMs. GSCs are the preferred
candidates to recruit TAMs into the tumor growing mass, as
they secrete several chemoattractant molecules like Interleukin
(IL) 6, IL1β, VEGF, colony stimulating factor 1 (CSF1), CXCL12,
and are able to induce their polarization into a pro-angiogenic
and immunosuppressive phenotype, which favors tumor growth
and escape from the immune surveillance (Lisi et al., 2017;
Manini et al., 2018).
Neurodegenerative Diseases
Neurodegenerative diseases are a group of illnesses characterized
by progressive functional damage of neurons leading
toward neuropsychiatric symptoms culminating with high
cognitive impairment. For example, neuronal damage
can be caused by amyloid-like protein deposition, genetic
alterations, or by secondary origins like immune diseases, or
metabolic dysregulations. Most of the NDDs are classified as
“proteinopathies,” since they are caused by misfolded protein
deposition, with the neurotoxic entity represented by the protein
tridimensional structure independently by protein sequence
or function. Normally these abnormal protein aggregates
are scavenged by autophagy-lysosome or by the ubiquitin-
proteasome system, mechanisms that demand high energy
consumption and can provoke mitochondrial dysfunction and
free-radical production. This oxidative stress leads to DNA
damage and microglia activation, neuroinflammation, and
dysfunction of neuronal transport, culminating with axonal
degeneration and neuronal death (Kovacs, 2016). In this regard,
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the misfolded protein effects are extensively investigated for
therapeutic strategies and as biomarkers.
Alzheimer’s disease is characterized by the deposition of Aβ
fibrils in brain parenchyma and vessel walls, associated to the
accumulation of aberrant phosphorylated Tau protein in neurons.
This disease is the main cause of dementia worldwide and its
etiology involves both genetic and environmental components.
The pathology mostly originates as sporadic form, but can also
occur from mutations in the APP gene (the precursor for Aβ
fibrils), in addition to presenilin (PSEN) 1 and PSEN2 that encode
a γ-secretase responsible for APP cleavage. Also, the expression
of the apolipoprotein E variant, ApoE4, represents a risk factor
for developing AD (Lane et al., 2018). These protein depositions
in the extracellular space, mainly in the isocortex, are called
amyloid plaques and are mostly composed of abnormally folded
Aβ subproducts of APP metabolism. Microglia activation by
Aβ oligomers increases the expression of triggering receptor in
myeloid cells 2 (TREM-2) and stimulates astrocytes leading to
inflammation and neuronal damage.
Parkinson’s disease (PD) is an α-synucleinopathy
characterized by the formation of Lewy bodies, predominantly
in neurons, along with the loss of dopaminergic neurons in
the substantia nigra pars compacta. These neurons regulate
the activity of the striatum, responsible for motor responses,
thus patients develop muscle rigidity, bradykinesia, postural
instability, and resting tremor. The family or hereditary form of
these diseases accounts for 10 to 15% of all cases. These patients
present mutations in some genes, such as SNCA, which encodes
α-synuclein associated with the progression and the severity of
the disease (Dehay et al., 2017). However, the sporadic form is
the most prevalent, and the etiology remains still unknown. It
was proposed that a combination of genetic susceptibility, diet,
environmental influences, viral infections, among others, might
act together to the onset of PD.
miRNAs
miRNAs belong to a group of small non-coding (nc) RNAs,
consisting of single-stranded RNAs of 20–24 nucleotides, that
assemble into ribonucleoprotein complexes called RNA-induced
silencing complex (RISC). For details, please refer to Hammond
(2015) and O’Brien et al. (2020). miRNAs regulate protein levels
without changing DNA sequence. In particular, a group of
miRNAs called Epi-miRNAs, can modulate the expression of
epigenetic machinery proteins (Moutinho and Esteller, 2017).
In addition, miRNAs can also bind to a nascent mRNA,
affecting transcription (Moutinho and Esteller, 2017). All of these
functions categorize miRNAs as part of epigenetic mechanisms.
Therefore, any deregulation of miRNAs production affects
gene expression leading to several diseases including cancer
(Baumann and Winkler, 2014).
Extracellular Vesicles
Extracellular vesicles are cell-derived particles that vary in size
and synthesis and carry several cargos like RNA, DNA, lipid,
and proteins, among others, of the cell of origin to a recipient
cell (Rahbarghazi et al., 2019). Hence, EVs represent a novel
type of cell-to-cell communication mechanism having potential
capability of modifying expression and behavior of the recipient
cell (Loghlen, 2017; Nogués et al., 2018; Willms et al., 2018).
Depending on size and origin, EVs can be classified at least in
three types: exosomes (30–100 nm), microvesicles or ectosomes
(50–1000 nm), and apoptotic bodies (100–200 nm) (Wang
M. et al., 2019). Exosomes are formed in a late endosomal
intracellular compartment called the multivesicular body (MVB),
arisen from an early endosome during the budding of the
membrane, generating intraluminal vesicles. Then, MVB can
either fuse with lysosomes for degradation or with the plasma
membrane to release the vesicles, called exosomes, into the
extracellular space. The transported exosomes can be then
recognized by the interaction of its transmembrane proteins with
the receptors of recipient cells, or alternatively, fuse directly
to the plasma membrane, by both clathrin-dependent and
independent pathways (Zhang J. et al., 2015). Microvesicles
are larger than exosomes and arise directly from outward
budding of the plasma membrane, generating vesicles toward
the extracellular space. Regarding apoptotic bodies [known
as apoptotic cell-derived extracellular vesicles (ApoEVs)], they
are produced by dying cells and therefore contain organelles
and cellular material that are destined to be degraded by
phagocytosis (You and Ikezu, 2019). More recently, it was
reported that ApoEVs are also able to transmit biological
messages from the cells from which they are originated to
nearby cells, and not simply garbage bags, as previously
believed (Xu X. et al., 2019). The three types of vesicles are
represented in Figure 1.
The most studied EVs are exosomes as they are secreted
by almost every cell type. They are modulators of several
physiological responses like immune responses, tissue repair, and
blood coagulation, among others (Arenaccio and Federico, 2017).
Particularly, they participate in tumorigenesis, for example,
by spreading from cell to cell oncogenic signaling such as
mutant EGFR. Besides, they are also involved in neurological
disorders, as they can load and transport several proteins involved
in neuropathies including Tau, Aβ-amyloid peptide, and α-
synuclein (Ageta and Tsuchida, 2019).
Remarkably, the most relevant connection between exosomes
and epigenetics are miRNAs since they can be loaded into
exosomes by the recognition of specific sequences called
EXOmotifs by one of four possible pathways, represented
in Figure 1: (a) the neural sphingomyelinase 2 (nSMase2)-
dependent pathway, (b) the sumoylated heterogeneous nuclear
ribonucleoprotein (hnRNP)-dependent pathway, (c) the sorting
signal encoded in the 3′ end of the miRNA, and (d) miRNA-
induced silencing complex (miRISC) (Rahbarghazi et al., 2019).
Any dysregulation of these pathways may lead to aberrant loading
and a potentially consequent disease progression; therefore,
these pathways could be exploited for therapy designs. miRNA-
containing-exosomes are unloaded by the receptor cell where
they play a role as negative regulators of transcription and
expression, or instead, function as receptors for immune cells
by acting like a toll-like receptor (TRL) receptor (Fabbri et al.,
2012), among others.
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FIGURE 1 | Schematic representation of the different types of EVs (exosomes, microvesicles and apo-EVs), its formation mechanisms and miRNA loading pathways
(nSMase2, hnRNP, 3′ sorting signal and mRISC).
Relationship Between Molecular
Pathways Dysregulated in GBM and PD,
and AD
There is increasing evidence showing brain cancer and
neurodegeneration can mutually influence each other.
For example, tumor cells secrete glutamate, which drives
neurotoxicity and neuronal death, and promotes tumor-
associated neurodegeneration (Seo and Park, 2019). Also, tumor
cells can communicate with and regulate microenvironment
functioning through several mechanisms, including EVs and
signaling molecules. In NDDs, cells also interact to modulate the
microenvironment; for example, microglia is able to secrete pro-
inflammatory factors via EVs, while astrocytes secrete EVs that
drive apoptosis, generating changes in the microenvironment
(for details refer to Martins et al., 2020). Therefore, modification
of the microenvironment appears to be an important shared
factor for the progression of both cancer and NDDs. Indeed,
this intercellular communication may explain the inverse
comorbidity between cancer and NDDs: low probability to
develop cancer in patients with certain CNS diseases, and vice
versa (Tabarés-seisdedos and Rubenstein, 2013; Ibáñez et al.,
2014). In support, several epidemiological studies reported an
inverse risk between the development of PD or AD and cancer
(Driver, 2014). In molecular terms, both cancer and NDDs share
signaling molecules but the underlying mechanisms could be
distinct (Seo and Park, 2019): cancers become immortal while
neurodegeneration kill cells. Therefore, it has become relevant
to investigate the linking signaling molecules identified in GBM
that also affect NDDs, to better understand the pathogenesis
of these diseases.
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Cancer and NDDs might share commonalities. Foremost,
neurons are affected in both diseases. In cancer the machinery
to repair DNA is frequently found mutated leading to genomic
instability. In the case of NDDs, during the reentry of neurons
into the cell cycle, similar mutations of the DNA repair machinery
can lead to protein accumulation, tangles, and formation of
plaques and ultimately to cell death (Houck et al., 2019).
For example, p53, the guardian of the genome, is a potential
molecular link between both diseases: p53 is often mutated in
cancer and active in NDDs (Driver, 2014). In relation with
miRNAs, miRNA-21 found in exosomes (Jesionek-kupnicka
et al., 2017; de Mooij et al., 2020) and−10b (Sun et al., 2019) were
linked to p53 in GBM. Interestingly, when the antago-miRNAs
were packed in nanoparticles and used for GBM treatment, they
decreased the tumor mass and led to cell cycle arrest (Teplyuk
et al., 2016). In NDDs, these miRNAs are mostly linked to
inflammation, and therefore the role of p53 pathways in NDDs
remains further to be evaluated.
Other potential links that play a significant role in the
development of both diseases are aging, oxidative stress, and
inflammation (Houck et al., 2019). For example, miRNAs-23a
(Li et al., 2020), −137 (Jiang Y. et al., 2019), −139 (Tang
et al., 2017) were linked to oxidative stress and inflammation.
Other potential commonalities between cancer and NDDs
worth examining are the nutrient-sensing mechanisms and
cellular senescence, which are related to aging and metabolism
deregulation. Cancer cells redirect their metabolism to increase
proliferation by fermenting glucose into lactate even when
mitochondria are fully active, a process known as the Warburg
effect (Liberti and Locasale, 2016). In NDDs, neurons are
dependent on the metabolic support provided by glial cells,
which can become senescent with aging (Houck et al., 2019). AD
patients are often hyperglycemic and have glucose metabolism
disorders such as diabetes, leading to a decreased utilization
of glucose in affected regions of the brain through disease
progression (Driver, 2014). In this regard, miRNA-7 was linked
to glucose metabolism in AD where it targets Insulin Receptor
Substrate-2 and Insulin Degrading Enzyme (Fernández-de Frutos
et al., 2019). Similarly, miRNA-338 contributes to metabolic
deregulation as a promoter of glycogen accumulation (Li C. et al.,
2019). In line with these findings, it is also frequent to detect
mitochondrial dysfunction related to energetic dysregulation in
NDDs and cancer, possibly as a consequence of mitochondrial
DNA mutations (Houck et al., 2019). In this context, miRNA-
137 controls mitochondria biogenesis and dynamics in NSCs,
leading to neuronal differentiation (Channakkar et al., 2020),
and also was linked to vesicle trafficking and exosomes in PD
(Jiang Y. et al., 2019); miRNA-210 was described to target
COX 10 and ISCU 1/2, linked to mitochondrial dysfunction
(Li et al., 2014).
Proteostasis should be also evaluated since protein processing
is critical for both diseases. In cancer, the ubiquitin-proteasome
system is upregulated to control the amount of proteins
needed to proliferate; in contrast, the opposite occurs in
NDDs (Houck et al., 2019). In PD, the ubiquitin-proteasome
system is downregulated leading to α-synuclein aggregation
into Lewy bodies. In AD, proteostasis is unbalanced because
of mutations and dysregulation of chaperones (miRNA-210
targets P4HB chaperone; Lee et al., 2015) and autophagy, leading
to Aβ-amyloid peptides and phosphorylated Tau deposits. In
this regard, Tau would become a potential nexus between
GBM and NDDs, as Tau is a contributor for GBM-associated
neurodegeneration, altogether with mostly upregulated miRNAs
−27a, −138, −195, −132, and −125 (Frigerio et al., 2013;
Dehghani et al., 2018; El Fatimy et al., 2018). As mentioned
above, AD is characterized by the deposition of Aβ fibrils in
brain parenchyma and vessels’ wall and by the accumulation of
aberrant phosphorylated Tau protein in neurons (Gargini et al.,
2019). In GBM, secreted CD44 leads to hyperphosphorylation
of Tau in the hippocampus (Lim et al., 2018); furthermore,
besides this neurodegenerative property, Tau was implicated in
GBM cells spreading: Tau expressed in GBM cells increases
their motility by modulating cytoskeleton dynamics in a
Rho-associated protein kinase (ROCK) signaling pathway-
dependent manner, it stabilizes microtubules, and generates
a rearrangement of the location of ROCK signaling pathway
molecules, leading to active actin cytoskeleton dynamics and
motility (Breuzard et al., 2019). Controversially, a recent
in silico analysis revealed that Tau expression is inversely
correlated with glioma progression: gliomas with higher levels
of Tau have a better prognosis (Gargini et al., 2019). In line
with this evidence, Tau was also found inversely correlated
with glioma progression and positively correlated with IDH
mutation (Gargini et al., 2020). Mechanistically, the increased
expression of Tau in IDH mutated gliomas impedes EGFR
signaling and the transdifferentiation into the more aggressive
mesenchymal subtype. Pin1 is also related to proteostasis, and
is downregulated in AD and upregulated in PD and cancer
(Seo and Park, 2019). Pin1 is a G1 checkpoint controller
that can bind to Tau, enhancing its dephosphorylation, and
can also interact with α-synuclein to promote its aggregation
(Seo and Park, 2019). Notably, upregulated proteins in NDDs
were found structurally disordered, showing a clear evidence
of proteinopathy. In contrast, upregulated proteins found in
cancer were structurally normal, indicating that these proteins
functions are normal during the development of tumor (Klus
et al., 2015). Furthermore, genes upregulated in NDDs were
usually less active in the normal physiological state. On the
contrary, genes upregulated in cancer are mostly already very
active in normal cells (Klus et al., 2015).
WNT is another interesting point to consider in tumor-
associated neurodegeneration, as cancer cells steal WNT factor
from normal neurons in the brain generating its death (Portela
et al., 2019). WNT pathway also drives NSC proliferation, so
it makes sense that the WNT pathway is downregulated in
NDDs and upregulated in cancer. Concordantly, miRNAs
−21 (Luo et al., 2017) and −338 (Li et al., 2018) are
deeply related to WNT pathway and, upregulated and
downregulated in GBM, respectively. Interestingly, miRNA-
338 sponge causes spontaneous neoplasm formation (Howe
et al., 2017). In NDDs, these miRNAs are mainly related to
protein deposits.
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FIGURE 2 | Expression of the most deregulated miRNAs in GBM and their influence on proliferation, angiogenesis, invasion, migration, and apoptosis of GBM.
miRNAs, frequently carried by EVs, act as epigenetic modulators and regulate several key processes in GBM. The deregulation of any of these miRNAs generates
abnormal gene expression which leads to disease progression. Black – miRNAs with unknown regulation in GBM; green – miRNAs upregulated in GBM; red –
miRNAs downregulated in GBM. Green circles show miRNAs positive effect on described processes; red circles show miRNAs negative effect on described
processes.
In the next sections, we will highlight the most commonly
deregulated miRNAs identified in both GBM and NDDs (in
particular AD and PD), discussing the up-to-date knowledge of
EVs and their potential link with their etiology.
EVs – miRNAs IN THE REGULATION OF
GBM
A recent major advance in GBM research was the discovery
of a communication between the tumor cells and the stroma,
mainly by EVs. One of the main players within the EVs are the
miRNAs as they constitute a repertoire that depends on the cell
of origin, and can regulate angiogenesis, proliferation, invasion,
and metastasis (Ingenito et al., 2019) (Figure 2).
Several approaches were used to create a miRNA profile
to classify them in patterns corresponding to different GBM
histotypes. For example, exosomes derived from GBM patients’
sera were analyzed to generate a list of novel miRNAs that
would be classifiers for gliomas grade II-III, IDH mutant, and
GBM IDH wt. Following this approach, the authors reported
that miRNAs 485, 486, and 543 were enriched in lower-grade
gliomas and miRNAs 182, 328, 339, and 340 behaved as
stable markers for GBM (Ebrahimkhani et al., 2018). Moreover,
the ExoCarta database1 provides information about exosomes
from diverse specimens, including miRNAs cargos and GBM
samples. Similarly, a database dedicated exclusively to miRNAs2,
enlists precursors and mature miRNA from several species.
Furthermore, a dataset dedicated to GBM is available in































TABLE 1 | Expression of the most deregulated miRNAs in GBM described in this work, their influence on proliferation, angiogenesis, invasion, migration, and apoptosis and their regulation in PD and AD.
miRNA GBM Neurodegenerative diseases: regulation Transported by EVs
Regulation Proliferation Angiogenesis Migration Invasion Apoptosis PD AD





+ (Luo et al.,
2017)
+ (Luo et al.,
2017)
Up (Su et al.,
2016)
Down (Juźwik et al.,
2019)
Yes (Van Der Vos et al.,
2016; Fernandes et al.,
2018; Guo et al., 2019;
Xiong et al., 2019; de
Mooij et al., 2020)
27a Up (Bhaskaran
et al., 2019)







Down (Frigerio et al.,
2013)
Yes (dos Santos et al.,
2018; Liu et al., 2018;
Wang J. et al., 2018)
23a Up (Bhaskaran
et al., 2019)
+ (Lian et al.,
2013)





Down (Agostini et al.,
2019; Barbagallo et al.,
2019)
Yes (Hsu et al., 2017;
Liu J. et al., 2019)




(Liu S. et al., 2019)
+ (Zhang S. et al.,
2018)
- (Liu S. et al.,
2019)






Up/Down (Li et al.,
2014; Zhu et al., 2015;
Swarbrick et al., 2019)
Yes (Jung et al., 2017;
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Liu et al., 2017; Zhou
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+ (Liu et al., 2014) - (Liu et al.,
2014)
* Up (Martins et al., 2020) Yes (Ebrahimkhani
et al., 2018)
15b Up (Xia et al., 2009;
Bhaskaran et al.,
2019)/Down (Wang
et al., 2017; Matos
et al., 2018)
- (Xia et al., 2009) + (Wang et al.,
2017)
* Down (Martins et al.,
2020)
Yes (Martins et al.,
2020)
124a Down (Fowler et al.,
2011)
- (Soldati et al.,
2013; Tivnan
et al., 2014)
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Yes (Morel et al., 2013;














+ (Chen et al.,
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Recently, it was developed an analysis of GEO database
specific for miRNAs involved in GBM and AD (Candido et al.,
2019); the authors scrutinized the datasets and provided an
in silico list of inversely regulated miRNAs and an ontological
analysis of the data. Also, a new database was built integrating
several features of GBM including genomic variants, gene
and miRNA expression in patients, DNA methylation profile,
among others5 (Yang et al., 2019a). It is important to note
that in some of these databases, the associations of some
miRNAs with EVs were not reported; therefore, it would
become a priority to identify and classify these miRNAs to
have a better perspective of the EVs-miRNAs role in these
pathologies, as for some of them, EVs-miRNAs are very
much unexplored.
The next sections will focus on the list of the most
dysregulated miRNAs in GBM created by Bhaskaran et al.
(2019), which is based on the TCGA database, summarizing
the up-to-date knowledge about these miRNAs related to
GBM biology, followed by potential association with EVs.
Furthermore, we evaluate the possible links between these
dysregulated miRNAs with AD and PD, to determine
potential molecular links for these diseases (Driver, 2014).
The information of the next section is summarized in Figure 2
and Table 1.
miRNAs Associated With Angiogenesis
and Proliferation in GBM
One of the most upregulated miRNAs in GBM samples is
miRNA27a (Bhaskaran et al., 2019), which belongs to the
miRNA-23a–27a–24-2 cluster (Wang N. et al., 2019). miRNA27a
regulates proliferation and tumorigenesis in GBM by inhibiting
the FOXO3a gene expression (Ge et al., 2013). Accordingly,
the administration of an antagonist for miRNA-27a using a
lentivirus carrier inhibits GBM proliferation in vitro (Feng
et al., 2012). Furthermore, miRNA-27a was proposed as a
potential marker to distinguish low-grade gliomas from GBM
(Rivera-Díaz et al., 2015). Furthermore, miRNA-27a, miRNA-
9 (which is known to regulate angiogenesis and proliferation;
Yu et al., 2018), and miRNA-23a, were differentially expressed
in mesenchymal subtypes compared with proneural subtypes,
indicating these three miRNAs might allow distinguishing
between GBM molecular subtypes. In addition, these miRNAs
segregate between groups of patients with increased and
decreased survival rates, suggesting a possible stratification
strategy to sort the patients in groups according to high
survival and low survival rates by using the three miRNA panel
(Marziali et al., 2017).
miRNA-139 is a tumor suppressor, downregulated in GBM
(Bhaskaran et al., 2019), which regulates diverse aspects of
tumorigenesis such as proliferation, apoptosis, migration, and
invasion. The low expression of miRNA-139 correlates with poor
prognosis and survival (Chen et al., 2018; Tian et al., 2019). One
work has provided evidence that a target of miRNA-139, called
NIN1 (RPN12) Binding Protein 1 Homolog (NOB1), which
encodes a subunit of the proteasome frequently deregulated
5http://bigd.big.ac.cn/gliomaDB
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in several tumoral processes, is upregulated and correlated
with increased metastasis (Shi et al., 2019). Another study
has identified several other targets of miRNA-139 in GBM:
latrophilin, a seven transmembrane domain containing (ELTD)
1, which encodes an orphan G protein-coupled receptor, and
cell cycle progression molecules, such as cyclin A and cyclin
D1, supporting its role as a regulator of GBM proliferation
(Dai et al., 2015). In addition, the EMT inducers zinc finger
E-box-binding homeobox (ZEB) 1 and ZEB2, involved in tumor
metastasis, were also identified as targets of miRNA-139. The
overexpression of this miRNA causes inhibition of migration
and invasion in GBM cell lines likely by downregulating
ZEB1 and ZEB2 (Yue et al., 2015). A recent study has also
identified syntenin as a downstream target of miRNA-139 in
glioma cells. In this context, inhibition of syntenin or miRNA-
139 overexpression led to a decreased proliferation, migration,
and invasion, and cell cycle arrest confirming previous studies
(Tian et al., 2019). Interestingly, induced myeloid leukemia cell
differentiation protein (Mcl)-1, an antiapoptotic molecule, also
identified as a target of miRNA-139, was able to sensitize GBM
cells to temozolomide (TMZ) by modifying Mcl-1 expression
(Li et al., 2013).
miRNA-137 is downregulated in GBM (Bhaskaran et al.,
2019) and associated with the inhibition of proliferation
and angiogenesis. Enhancer of zeste homolog (EZH) 2, a
histone-lysine N-methyltransferase enzyme involved mainly in
the cell cycle, is a target of miRNA-137 and therefore the
inhibition of this miRNA led to increased proliferation and
angiogenesis, pointing at miRNA-137 as a tumor suppressor
(Sun et al., 2015). Another study revealed that miRNA-
137 overexpression, by targeting EGFR, led to decreased
proliferation and increased apoptosis (Zhang et al., 2017c),
further suggesting that low expression of miRNA-137 is
correlated with poor prognosis. In addition, miRNA-137 targets
genes involved in both neurogenesis and tumorigenesis in
GBM, such as c-KIT, CDK6, AKT2, CDC42, YBX1, and
transforming growth factor (TGF) β2 (Tamim et al., 2014).
Furthermore, these targets were shared with miRNAs −7,
−124, and −128, all of these miRNAs are tumor suppressors
that will be discussed in the following sections. In addition,
miRNA-137 (among other tumor suppressor miRNAs) also
targets Musashi-1 expression, a self-renewal and tumorigenic
factor in GBM cells, indicating its protective role in this
type of tumors (Vo et al., 2011; Velasco et al., 2019).
Indeed, based on their opposite expression patterns and
function in glioma cells, where they share a common network
of target genes, it was further suggested that the balance
between miRNA expression could have a critical impact
on the dynamics of cellular states affecting tumorigenesis
and NDDs development. In addition, miRNA-137 was also
reported to regulate mitochondrial dynamics and biogenesis
in human induced neural stem cells (hiNSCs) to promote
neuronal differentiation. In these cells, miRNA-137 increases
the expression of stem cell markers: OCT4 and SOX2, as
these molecules have a binding site for miRNA-137 in the
promoter (Channakkar et al., 2020). Further exploration of this
regulatory network and the role of these master regulators in the
modulation of NSC fate would be critical for the understanding
of neural maturity, neurological diseases, and GBM cell plasticity
and development.
miRNA-15b is upregulated in GBM to induce cell cycle
arrest by targeting CCNE1, a protein related to G1/S phase
progression (Xia et al., 2009; Bhaskaran et al., 2019). However,
other authors found it downregulated in GBM cells and tissues,
demonstrating a tumor suppressor function via the targeting
of IGF1R, an anti-apoptotic gene (Wang et al., 2017; Matos
et al., 2018). Therefore, miRNA-15b low expression is correlated
with poor survival (Wang et al., 2017). Moreover, miRNA-
15b and miRNA-21 were studied as possible biomarkers in
blood samples to distinguish between patients with or without
gliomas (Ivo D’Urso et al., 2015). Finally, miRNA-15b levels are
decreased in sera from patients with malignant astrocytomas
(Jin et al., 2017).
EVs Containing miRNAs in GBM
Angiogenesis and Proliferation
Recent studies addressing the connection between exosomal
miRNAs and GBM have begun to disclose many processes
of its biology. However, small information is available for
miRNAs traveling by GBM exosomes. As an example, miRNA-
9 transported by glioma-derived exosomes is upregulated by
MYC and OCT4 in GBM cells and causes the dysfunction of
the Hypoxia-Inducible Factor (HIF)-1α/VEGF signaling pathway
(Chen et al., 2019). miRNA27a is also characterized as a regulator
of vital processes in tumor development, including angiogenesis,
migration, invasion, proliferation, and apoptosis, and even in
tumor resistance and sensitivity for drugs in many types of cancer
(Li X. et al., 2016). Detection of miRNA-137 in sera from GBM
patients also determined that its low content was correlated with
poor prognosis, indicating miRNA-137 could be a prognosis
marker (Li X. et al., 2016). Furthermore, miRNA-137 was studied
in exosomes related to PD, which will be discussed in the next
section (Jiang Y. et al., 2019).
miRNAs Associated With Migration and
Invasion in GBM
Tumor migration and invasion are the major contributors to
poor prognosis and relapse. miRNA-21 is highly upregulated
in tumor cells, mainly in perivascular niches, and promotes
migration and invasion through the β-catenin pathway (Luo
et al., 2017). In addition, miRNA-21 might control proliferation
modulating the p53 pathway and by interacting with CASC2
long-non-coding (lnc) RNA (Jesionek-kupnicka et al., 2017).
Interestingly, Sox2 (stem cell marker) and miRNA-21 are
expressed in mutually exclusive patterns in GBM (i.e., high
miRNA-21/low Sox2 and low miRNA-21/high Sox2), indicating
the existence of two populations of GBM patients with distinct
phenotypic features and clinical outcomes. The low miRNA-
21/high Sox2 pattern is associated with a better prognosis,
consenting a new classification to predict patient survival
(Sathyan et al., 2015). Besides, miRNA-21 is one of the
miRNAs whose overexpression leads to radioresistance in GBM
(Toraih et al., 2019).
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miRNA-23a is upregulated in GBM samples according
to the TCGA database (Bhaskaran et al., 2019) and was
recently identified as a key modulator of GBM invasion by
targeting Homeobox 10 and increasing ras homolog family
member (Rho)A, RhoC, and urokinase-type plasminogen
activator receptor (uPAR) expression (Hu et al., 2013; Yachi
et al., 2018). In addition, glial-mesenchymal transition markers
metalloproteinase (MMP) 2 and MMP9, were deregulated by
this miRNA, indicating an enhanced tumorigenesis. Accordingly,
miRNA-23a increases tumor growth, migration, and invasiveness
by possibly targeting apoptosis protease-activating factor (APAF)
1, which is involved in apoptosis induction (Lian et al., 2013).
Given these characteristics, miRNA-23a has been evaluated as
a potential GBM marker for diagnosis, along with miRNA-
9 and miRNA-27a, to distinguish the mesenchymal from the
proneural subtype (Marziali et al., 2017); however, miRNA-
23a is not expressed solely in the CNS and consequently,
it may not be used for a diagnosis strategy (Ye et al.,
2017). In addition, another study provided a comparative
analysis of miRNA patterns between GSCs and non-GSCs
(Sana et al., 2018). The authors uncovered nine miRNAs
upregulated in GSCs compared to non-GSCs, and, among
these, miRNA-9 was inversely correlated with patient survival
(Sana et al., 2018).
In the normal brain, miRNA-124a is expressed in
developing neurons to ensure its correct maturation (Cao
et al., 2007), whereas in GBM is severely downregulated and
acts as a tumor suppressor by mainly regulating migration
and invasion. It targets IQ motif containing GTPase
activating protein (IQGAP) 1, laminin c1, and integrin
b1 proteins (Fowler et al., 2011; Bhaskaran et al., 2019);
in addition, its expression was negatively correlated with
the expression of EMT genes including vimentin (VIM),
chitinase-like glycoprotein (YKL)-40, Nestin, and Notch2
(Ma et al., 2012).
miRNA-338 regulates migration, invasion, proliferation, and
apoptosis of tumor cells and was found to be downregulated
in GBM possibly due to hypermethylation of its promoter
(Han et al., 2017). Recently, the EGF-containing fibulin-like
extracellular matrix protein 1 (EFEMP1), which controls MMPs,
and the metalloproteinase inhibitor (TIMP)-3 were identified as
targets of miRNA-338 (Klenotic et al., 2004; Lei et al., 2017). The
down-regulation of EFEMP1 inhibits migration and apoptosis
in miRNA-338 overexpressing GBM cells. However, miRNA-
338 was also found to be upregulated in GBM, when compared
to lower grades gliomas, and to promote tumor invasiveness
by increasing the expression of MMP2 by downregulating
t-shirt zinc finger homeobox (TSHZ) 3, a transcription factor
involved in development (Li et al., 2018). Furthermore, miRNA-
338 targets embryonic pyruvate kinase M2 (PKM2), frequently
overexpressed in tumors, preventing the transcriptional activity
of β-catenin and leading to decreased tumor growth and
increased survival of the animal model (Han et al., 2017).
Moreover, it was discovered that miRNA-338 is regulated by
LINC00689, a long non-coding RNA, whose expression is
incremented in glioma tissue where it promotes glycolysis,
migration, proliferation, and invasion (Liu X. et al., 2019).
EVs Containing miRNAs in GBM
Migration and Invasion
Recent evidence indicates that exosomal miRNAs have control
over glioma invasion by modulating their downstream targets
and facilitating a spatial communication between tumor cells
and their surroundings. For example, miRNA-21 is one of
the most upregulated miRNAs traveling by EVs in GBM (de
Mooij et al., 2020). When an engineered exosome containing
miRNA-21 sponge (a competitive inhibitor for the target
miRNA; Ebert et al., 2007) is delivered to GBM cells in
culture, these exosomes suppress GBM proliferation and increase
apoptosis. Furthermore, miRNA-21- loaded sponge exosomes
also decreased the tumor volume in rat models (Monfared
et al., 2019). In addition, miRNA-21/miRNA-451 shows a very
interesting nexus between microglia, glioma, and EVs. These
miRNAs, enriched in glioma-derived exosomes, have a great
impact on microglia, where they reduce c-Myc expression,
a transcription factor regulating several cellular processes
including cell cycle and apoptosis, and promote a shift toward an
immune suppressor phenotype, supporting glioma progression
(Van Der Vos et al., 2016; Guo et al., 2019).
miRNA-124 is another example of miRNA-loaded in
exosomes detected in GBM patients, which was correlated with
high grade gliomas, and therefore designated as an onco-miRNA
(Tabibkhooei et al., 2020). The delivery of anti-miRNA-124 with
a nanocarrier was shown to be effective against GBM by reducing
proliferation and migration and inducing cell sensitization
to TMZ (Jana et al., 2019). miRNA-124a-loaded exosomes
from mesenchymal stem cells (MSCs) were also evaluated as a
potential therapeutic strategy to treat GBM (Lang et al., 2018;
Bajetto et al., 2020). Both in vivo and in vitro treatment with
these exosomes reduced the tumorigenesis, tumor growth, and
increased the survival.
Regarding miRNA-338 loaded exosomes, they were
characterized in the context of AD and will be discussed in
the next section.
miRNAs Associated With Apoptosis in
GBM
miRNAs also participate in the modulation of the apoptosis
pathway in GBM. This is the case of miRNA-210, which
is upregulated in GBM and decreases apoptosis by targeting
ROD1 (Zhang S. et al., 2018); it was also found upregulated in
GSC spheroids under acute hypoxia (Rosenberg et al., 2015).
miRNA-210 was proposed as a regulator for TMZ therapy
resistance (Lee et al., 2015), since this miRNA is downregulated
in TMZ-resistant GBM and its upregulation reverses this
condition by targeting P4HB chaperone. Controversially, another
study revealed that miRNA-210 is downregulated in GBM
where modulates migration and invasion by targeting BDNF
(Liu S. et al., 2019).
Another example is miRNA-7, which is downregulated
in GBM and promotes TRAIL-induced apoptosis (Bhaskaran
et al., 2019). Accordingly, forced expression of miRNA-7 and
exposure to TRAIL raised the proportion of apoptotic GBM cells
(Zhang et al., 2017b).
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miRNA-10b is another miRNA highly upregulated in GBM
samples (Bhaskaran et al., 2019), but, interestingly, it is not
expressed in normal brain tissue (Gabriely et al., 2011).
Regarding apoptosis, miRNA-10b targets BIM (Gabriely et al.,
2011), a molecule that participates in the mitochondrial
cell death pathway, hence preventing apoptosis in GBM.
Furthermore, together with miRNA-222, miRNA-10b prevents
apoptosis by p53 dependent and independent pathways (Sun
et al., 2019): miRNA-10b and miRNA-222 target PTEN,
therefore activating MDM2 and inhibiting p53; and also
inhibit PUMA and BIM, respectively. Besides, miRNA-10b
also targets p21 and E2F1, contributing to deregulation of
cell cycle, and promotion of proliferation and tumor growth
(Teplyuk et al., 2015). In GBM cells, miRNA-10b was also
shown to mediate the effects of and to be upregulated
by TGF-β1 (Ma et al., 2017). Furthermore, miRNA-10b
increases proliferation, invasion, and EMT by targeting PTEN,
caspase-9, Apaf-1, and E-cadherin (Ma et al., 2017). As
mentioned above, miRNA-10b is not expressed by normal
brain tissue, therefore constituting an interesting candidate for
therapeutic approaches.
miRNA-106b is another highly upregulated miRNA in GBM
samples. It has been described as an inhibitor of apoptosis and as
a proliferation enhancer by targeting retinoblastoma-like 1/2 and
CASP8 (Liu et al., 2014). Interestingly, miRNA-106b decreases
NKG2D, an activating ligand for NK cells, pointing at an immune
suppressor miRNA (Codo et al., 2014).
miRNA-155 is highly expressed not only in GBM (Bhaskaran
et al., 2019) but also in a number of other cancers (Bayraktar
and Van Roosbroeck, 2018). It promotes proliferation of GBM
cells by targeting both MXI1, a c-Myc inhibitor (Zhou et al.,
2013) and targets a p38 isoform which promotes apoptosis (Liu
et al., 2015). In addition, it modulates invasion by increasing the
secretion of MMP2 and MMP9 (Liu et al., 2015). Furthermore,
its downregulation sensitizes GBM cells to TMZ and reduces
their proliferation (Liu et al., 2015). miRNA-155 is derived from
the long non-coding RNA, miRNA-155 hostgene (HG), which
has been described mainly as an EMT promoter (Cui et al.,
2019). In GBM, miRNA-155HG was also correlated with poor
prognosis, malignancy, EMT and tumor progression; these effects
were the result of the modulation of miRNA-155 expression and
its downstream target genes, such as protocadherin 7 and 9, both
acting as tumor suppressors (Wu et al., 2017).
EVs Containing miRNAs in GBM
Apoptosis
miRNA-210 was found in EVs isolated from GBM patient sera
showing a significant upregulation when compared with the
control group. Therefore, EV-miRNA-210 could eventually be
considered as a marker for GBM (Lai et al., 2015).
Even though miRNA-10b has not yet been detected in
exosomes from GBM, the delivery of miR-10b antisense
oligonucleotide inhibitors to mouse orthotopic xenografts
resulted in a slow-down of tumor progression (Teplyuk et al.,
2016). Also, the intravenous injections of encapsulated antago-
miRNA-10b, together with antago-miRNA-21, in synthesized
nanoparticles (Malhotra et al., 2018), showed cell cycle arrest and
decreased of tumor volume after TMZ treatment.
miRNA-7 loaded exosomes were detected in TRAIL-
overexpressed MSCs transiently expressing miRNA-7, indicating
its EV-loading property. When injected into the tail vein of
GBM-xenografted mice, these cells promoted GBM cell death
and decreased tumor growth (Zhang et al., 2017b). Another
study reported that miRNA-7 delivered to GBM by several
methods such as adeno-associated virus, induced GBM cell
apoptosis by targeting EGFR, linked to upregulation of death
receptor 5 and subsequent TRAIL-induced cell death (Bhere
et al., 2018). Moreover, miRNA-7 overexpression in GBM
cells diminished migration and invasion, targeting SATB1
(Yin et al., 2019). Furthermore, miRNA-7 was also linked to
anti-angiogenic effects: its delivery in polymeric nanoparticles
to GBM xenografts, diminished tumor growth and decreased
angiogenesis (Babae et al., 2014). Even though miRNA-7
containing EVs have not yet been isolated from GBM, this
miRNA makes a promising candidate for therapeutic approach,
since it targets several physio-pathological processes in GBM.
miRNA-106b was only detected in exosomes derived from sera
from patients with low grades gliomas, but not yet from GBM
patients (Ebrahimkhani et al., 2018).
miRNAs AS MODULATORS OF
PARKINSON’S AND ALZHEIMER’S
DISEASES
In Figure 3 and Table 1, we summarized the expression patterns
of miRNAs in AD and PD described in this work. We will
focus on these two main NDDs to discuss about the inverse
comorbidity with cancer previously described (Driver, 2014).
miRNAs Modulating Alzheimer ’s Disease
The impaired learning and memory characteristic of AD is
correlated with increased miRNA-139 levels in the hippocampus
of senescence-accelerated mouse-prone (SAMP) 8 mice. This
effect was associated with the targeting of cannabinoid receptor
type 2, involved in microglia inflammatory responses (Tang
et al., 2017). Besides, miRNA-139 decreased pro-inflammatory
responses by targeting ICAM-1 and CD40. Overall, it was
determined that the inhibition of miRNA-139 with antagomir
injection reduced AD pathology. It is important to note that
in GBM, miRNA-139 is downregulated and acts as a tumor
suppressor. Since this miRNA participates in inflammatory
responses, it would be interesting to evaluate its role in
this process in GBM.
miRNA-137, which regulates the NF-kB pathway by targeting
(TNFα)-induced protein 1 (TNFAIP1), is downregulated in AD.
In support, miRNA-137 overexpression decreases Aβ toxicity
in neurons by inhibiting the NF-kB pathway (He et al., 2017).
Besides, Aβ peptide induces miRNA-137 downregulation in
cultured neurons.
A high miRNA-7 level is associated with high Aβ protein
deposits in AD. This miRNA targets Insulin receptor, Insulin
Receptor Substrate-2, and Insulin Degrading Enzyme, which
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FIGURE 3 | Expression in AD and PD of the most deregulated miRNAs in GBM. AD is characterized by the deposition of Aβ fibrils in the brain parenchyma and
vessel walls and by the accumulation of aberrant phosphorylated Tau protein in neurons. PD is an α-synucleinopathy characterized by the formation of Lewy bodies
by the accumulation of α-synuclein predominantly in neurons, causing the loss of dopaminergic neurons. In both diseases, abnormal regulation of miRNAs plays a
key role in the onset and progression of the diseases. Black – miRNAs with unknown regulation in AD and PD; green – miRNAs upregulated in AD and PD; red –
miRNAs downregulated in AD and PD.
are critical to glucose homeostasis and Aβ metabolism in
AD (Fernández-de Frutos et al., 2019). In addition, miRNA-7
was found directly correlated with an increase of Aβ protein
deposition in neurons and decrease clearance by microglial cells
(Fernández-de Frutos et al., 2019).
miRNA-132 has a protective effect in AD as it is involved
in neuronal plasticity, Tau downregulation, and protection
from glutamate excitotoxicity (El Fatimy et al., 2018). Despite
this neuroprotective role, miRNA-132 was associated with Tau
hyperphosphorylation by targeting glycogen synthase kinase
3β (GSK3β) and sirtuin 1 (SIRT1), responsible for Tau
phosphorylation and acetylation, respectively (Dehghani et al.,
2018). Other miRNAs also regulate SIRT1 expression, including
miRNA-181c and miRNA-9. Another example is miRNA-138,
which is upregulated in AD and reduces the expression of
SIRT1, and also increases the activation of GSK3β promoting
Tau aggregation (Dehghani et al., 2018). Therefore, SIRT1 would
be a candidate node that might link between these miRNAs to
AD pathogenesis.
miRNA-195 is involved in the formation of Tau aggregates and
Aβ plaques by upregulating β-secretase (BACE) 1. It also activates
CDK5, which leads to Tau hyperphosphorylation, and nuclear
factor kappa B (NFkB) activation, causing neuroinflammation
(Dehghani et al., 2018). miRNA-125b also regulates Tau
phosphorylation by activating MAPK. It also regulates synapsis
by targeting a subunit of N-methyl- D-aspartate (NMDA)
glutamate receptors (Dehghani et al., 2018).
Recently, downregulated miRNA-23a was detected in sera
from AD patients that carry a SNAP-25 genotype, which is
correlated with brain atrophy and cognitive decline (Agostini
et al., 2019). In addition, deregulated miRNA-23a was found in
both AD and PD, and associated to ongoing neurodegenerative
processes. miRNA-210 was also found reduced in AD patients
sera and cerebro-spinal fluid (CSF), and correlated with
diminished VEGF expression, an angiogenic growth factor,
and with the severity of the disease (Zhu et al., 2015;
Swarbrick et al., 2019).
miRNA-124a is implicated in AD pathogenesis because it
downregulates hypoxia- associated Aβ formation through the
disinhibition of BACE1 (Zhang et al., 2017a). This is an important
finding that would corroborate the theory of vascular dysfunction
and hypoperfusion during the pathogenesis of AD (Govindpani
et al., 2019). Similarly, overexpressed miRNA-338 targets BACE1
and reverts neuroinflammation and Aβ-amyloid formation (Qian
et al., 2019). Interestingly, the knockdown of this miRNA by
the injection of the miRNA-338-sponge in mice brain promoted
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spontaneous neoplasm formation, histologically reminiscent
of GBM with neuronal morphological disorganization and
increased proliferation (Howe et al., 2017). This data is of utmost
importance as miRNA-338 is severely downregulated in GBM
(Han et al., 2017), and the solely fact that its downregulation
promotes neoplasm formation indicates that it is a key player
for developing brain tumors. Besides, miRNA-338 is highly
expressed in mature neurons, and its overexpression in GBM
cell lines decreased their proliferation (Howe et al., 2017). Worth
to notice, both miRNA-124a and −338 target BACE1 and are
upregulated in AD and downregulated in GBM. In this regard,
Aβ peptide accumulation has been found in GBM samples from
patients and mouse models (Zayas-Santiago et al., 2020), mainly
in glioma blood vessels walls and in GBM cells that expressed
GFAP. As miRNA-124a and −338 promote vascular dysfunction
and inflammation, it would be interesting to know if these
miRNAs are involved in Aβ accumulation in GBM.
Likewise, a search for common miRNAs between cancer and
AD allowed the identification, in both diseases, of a common
expression of miRNA-27a, miRNA-7 and miRNA-21, all targeting
EGFR (Battaglia et al., 2019). Despite that GBM was not evaluated
in this work, all of these miRNAs are important as we described
above. Other miRNAs shared by AD and GBM are miRNAs-9,
106b,−124,−132 and 138, all related to Tau phosphorylation. In
addition, miRNAs-9 and 132 were also linked to other Tau post-
translational modifications, such as acetylation (Bazrgar et al.,
2020). In addition, miRNA-9, −124, −132 and −137, among
others were related to Tau alternative splicing.
EVs-miRNAs in Alzheimer’s Disease
Recently, one revision of exosomes modulating AD has classified
EVs-miRNAs according to the biological fluids collected for
the study (Martins et al., 2020). They observed that miRNAs
in serum-derived EVs were often upregulated, whereas in
plasma, were mostly downregulated. From the miRNAs found
in serum-derived EVs, it is worth to point out that miRNA-
23a and miRNA-106b were upregulated, and both target key
enzymes of APP and Tau metabolism. Both miRNAs are also
upregulated in GBM (Bhaskaran et al., 2019), where miRNA-
23a modulates mainly migration and miRNA-106b regulates
apoptosis and proliferation.
miRNA-15b and 193b are downregulated in serum-derived
EVs from AD patients, yet their targets in AD are unknown.
By contrast, in GBM, miRNA-15b is upregulated and regulates
cell cycle, whereas miRNA-193b is poorly described: only one
study found it upregulated in pericytes of GBM microvasculature,
where it modulates the expression of PDGFRβ and regulates
proliferation (Xu and Li, 2016). These miRNAs were not
identified in GBM exosomes yet, nonetheless, results from AD
EVs are promising to be further exploited in GBM.
In plasma-derived EVs, miRNA-21, miRNA-23a, miRNA-132,
miRNA-193b, and miRNA-338 are downregulated (Martins et al.,
2020). Notably, miRNA-23a shows an opposite accumulation
between serum and plasma. Among these miRNAs, they
are all upregulated also in GBM, except miRNA-338, which
is downregulated (Bhaskaran et al., 2019). miRNA-21 is
downregulated in AD (Juźwik et al., 2019); however, one work
has shown that miRNA-21-containing exosomes derived from
SH-SY5Y neuroblastoma cells transfected with the Swedish
mutant of APP695 (SHSwe), induce microglia M1 polarization,
which releases pro-inflammatory cytokines such as high mobility
group box 1 protein (HMGB1), tumor necrosis factor (TNF)-
α, S100 calcium-binding protein B (S100B), and further secretes
miRNA-21-containing exosomes, probably as a positive feedback
mechanism (Fernandes et al., 2018). These facts led to consider
miRNA-21 as a potential enhancer of AD pathogenesis since
the pro-inflammatory M1 polarized microglia downregulate
genes involved in Aβ-protein clearance and thus promotes the
accumulation of oligomers and disease progression (Hickman
et al., 2008). On the contrary, another work described that
the increase of miRNA-21 content in an AD mouse model
reduced the cognitive deficit, diminished the Aβ-deposition, and
decreased inflammatory markers (Cui et al., 2018). The artificial
increase of miRNA-21 was achieved by the administration of
exosomes from hypoxia-preconditioned MSCs.
In CSF of AD patients, miRNA-27a and miRNA-132 are
upregulated and miRNA-193b is downregulated (Martins et al.,
2020). Another work found that reduced miRNA-27a content in
CSF was associated to elevated Tau and reduced Aβ-amyloid CSF
levels (Frigerio et al., 2013).
Another recent study analyzed EV-miRNAs from AD patient
plasma, and compared miRNAs derived from total EVs with
those from neural origin (Serpente et al., 2020). Thus, neural-
derived EVs (NEVs) were isolated by selecting the EVs
expressing LCAM1. They found that miRNA-23a was present
and upregulated in both EVs and NEVs, though miRNA-15b and
miRNA-27a were upregulated in total EVs, but not in NEVs.
These results support the hypothesis that these miRNAs are
dysregulated in both AD and GBM.
A recent study analyzed the content of EVs from AD, Lewy
bodies dementia (also characterized by the presence of Aβ-
amyloid plaques and hyperphosphorylated Tau) and healthy
patients. The analysis of plasma-derived EVs, determined that
miRNA-21 and miRNA-451 allowed the discrimination between
AD and dementia with Lewy bodies, and therefore could
represent a future diagnosis strategy (Gámez-Valero et al., 2019).
In GBM, EVs containing miRNA-21 and −451 shift microglia to
an immune suppressor phenotype, as described above (Van Der
Vos et al., 2016; Guo et al., 2019), hence it would be interesting
to know if this pair of miRNA produces the same effects in AD,
since it has a major inflammatory component. Furthermore, a set
of four miRNAs (23a, 126, let-7i, and 151a) were decreased in EVs
from AD compared to control. These results are in disagreement
with previously discussed studies, stating that miRNA23a is
upregulated. Altogether, there is still much controversy regarding
EVs cargo analysis, and these will stay as long as a standardized
method is developed and validated.
miRNAs Modulating Parkinson’s Disease
In PD, the upregulation of miRNA-21 induces α-synuclein
expression, indicating a detrimental role of this miRNA (Su
et al., 2016). This upregulation contrasts with the downregulation
described in AD (Juźwik et al., 2019).
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Recent studies using cell lines treated with the neurotoxin 1-
methyl-4-phenylpyridinium (MMP+), which in vivo reproduces
the same neurodegeneration pattern observed in PD patients,
induced the upregulation of miRNA-210, which correlated
with poor disease outcome and dopaminergic neuron damage
by targeting BDNF (Zhang S. et al., 2018). This factor is
neuroprotective, improving neuronal survival, and synaptic
function and plasticity (Winham et al., 2019); conversely,
in GBM, BDNF promotes tumor cell stemness (Wang X.
et al., 2018). This inverse relation would need further studies
since the same miRNA targeting the same factor produces
different outcomes.
miRNA-124a is also decreased in PD patients, but, when
delivered to the subventricular zone (SVZ) with encapsulating
nanoparticles in a 6-hydroxydopamine (6-OHDA) mouse model
for PD, promotes improvement of motor symptoms (Saraiva
et al., 2016). The family of miRNA-124 has been deeply studied in
PD as it targets several neuroprotective pathways and molecules:
STAT-3, calpain-1, Bim, Annexin V, and MEKK3. In GBM,
miRNA-124a is also severely downregulated and acts as a
tumor suppressor by modifying mainly migration and invasion,
although there is no common known target with PD (Fowler
et al., 2011; Bhaskaran et al., 2019).
miRNA-137 is upregulated in patients with PD, nevertheless
no correlation was found between this increase and the severity
of the disease (Li et al., 2017); furthermore, miRNA-137 is also
elevated in plasma and could represent a candidate biomarker
for PD (Li et al., 2017). As discussed above, miRNA-137 is
downregulated in GBM and acts as a tumor suppressor, and
targets EZH2 to modulate proliferation and angiogenesis (Sun
et al., 2015). Since epigenetic dysregulation accompanied by
cognitive dysfunction is a common feature in many neurological
disorders, it would be interesting to know the epigenetic status
regarding EZH2 activity in PD and AD patients.
Downregulation of miRNA-7 promotes α-synuclein accumu-
lation contributing to the loss of dopaminergic neurons (Zhou
et al., 2016; McMillan et al., 2017). Likewise, it was recently
reported that this miRNA promotes the degradation of α-
synuclein by autophagy (Kovacs, 2017). Besides, miRNA-7
targets NOD-, LRR-, and pyrin domain-containing protein
(NLRP) 3, a component of inflammasomes that is increased
in PD patients and PD-mice models (Zhou et al., 2016).
Moreover, miRNA-7 injection into the brain of a PD-mice model
promotes the disassembly of the inflammasomes, decreasing the
neuroinflammation, and protecting the dopaminergic neurons
from degeneration. Furthermore, miRNA-7 overexpression
protected cortical neurons from MPP+-induced toxicity,
favoring neuronal viability, and preventing apoptosis (Fragkouli
and Doxakis, 2014). In GBM, miRNA-7 is downregulated
and controls apoptosis (Zhang et al., 2017b), whereas in
PD, it regulates α-synuclein degradation and inflammation
(Kovacs, 2017).
EVs-miRNAs in Parkinson’s Disease
In PD, compared to other NDDs, only a few studies described the
pathogenetic role of EVs-miRNAs. One study evaluated miRNA-
27a as a possible biomarker in CSF-exosomes (dos Santos et al.,
2018), similar to AD. Another study reported that mice serum
exosomes enriched with miRNA-10b generated M2 polarization,
indicative of the induction of an anti-inflammatory phenotype
(Zhou et al., 2017). The level of miRNA-10b is decreased and
positively correlated with age of onset of PD (Hoss et al., 2016). It
would be interesting to determine the targets affected by miRNA-
10b to promote M2 polarization in PD and the ones that promote
apoptosis in GBM to deep in the molecular causes and possible
therapeutics for these diseases.
It was demonstrated that miRNA-124a is transferred from
neurons to astrocytes via exosomes and this interaction promotes
the expression of GLT1, a glutamate transporter (Morel et al.,
2013). Another work determined that miRNA-137 containing
sera-derived exosomes led to oxidative stress injury in neurons by
targeting OXR1, while exosomes carrying miRNA-137 antagomir
alleviate the symptoms, representing a possible therapeutic
approach (Jiang Y. et al., 2019).
A recent review collected literature regarding EVs-miRNAs
in PD (Wang and Zhang, 2020). Among the miRNAs we
analyzed, elevated miRNA-23a and miRNA-195 were found
in serum-derived exosomes, like in AD, while miRNA-19b is
downregulated both in serum- and in CSF-derived exosomes.
The targets of miRNA-19b and −195 miRNA have not been yet
elucidated in PD. However, as far as miRNA-19b is concerned,
in silico GO analysis determined that its targets are involved
in macromolecule biosynthetic process (Uwatoko et al., 2019).
Another recent work demonstrated that miRNA-21, miRNA-
210, and miRNA-155 are present in plasma-derived EVs from
a pre-motor PD model, with the total number of EVs also
incremented (Sancandi et al., 2020). As discussed above, miRNA-
21 represents a common dysregulated EV-miRNA among all
the diseases studied, where it fulfills different functions. For
example, in the MMP+ PD cell line model, miRNA-21 was
increased, and the treatment with miRNA-21 inhibitor reduced
apoptosis, improved survival and inhibited the production of
pro-inflammatory cytokines (Mao and Ding, 2019); in AD, when
traveling by EVs, it also modulates microglia polarization toward
an M1 phenotype (Hickman et al., 2008), whereas in GBM, it
promotes an immune suppressor shift in microglia (Van Der Vos
et al., 2016; Guo et al., 2019). The main shared aspect of this
miRNA function in the different diseases studied, is microglia
polarization, thus it would be interesting to further explore the
targets affected by this miRNA in this process as a possible
therapy to be developed.
miRNA-210 was found upregulated in MMP+ PD model in
SH-SY5Y cells, in which, targeting BDNF, contributes to cell
damage (Zhang S. et al., 2018). Interestingly, miRNA-210 targets
BDNF in both PD/AD and GBM, and as we described above,
it is a neuroprotective factor in AD and PD, and protumoral in
GBM. It has not yet been found in exosomes from GBM or AD,
nevertheless, it is present in CSF and serum from AD patients, so
further research for this miRNA would be interesting to develop
possible future therapies. miRNA-155 level is increased in an
in vivo model of PD in which α-synuclein expression is induced
by adenovirus inoculation and, similarly to AD (Slota and Booth,
2019), was markedly linked to inflammation (Thome et al., 2016),
whereas in GBM it was related to cell proliferation, apoptosis and
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migration. However, further research for the role in inflammation
needs to be addressed as it has not yet been described in GBM.
CONCLUSION
Here we describe and discuss the molecular pathways shared
by GBM and NDDs, as an approach to explaining the
epidemiological mutual exclusive comorbidities, while analyzing
classical pathogenic mechanisms would be too difficult. Yet, a no
clear correlation of miRNA expression pattern observed herein
GBM and NDDs. However, a similar approach dealing with
these inverse comorbidities between cancer and NDDs found
that specific pathways such as WNT, p53, protein folding, and
protein degradation are inversely regulated (Ibáñez et al., 2014).
Indeed, from our analysis, some miRNAs inversely expressed
and targeting the identical molecule or modulate the same
pathway in both GBM and NDDs would represent attractive
entry points to a deeper understanding of the underlying
molecular physiopathological mechanism. For example, miRNA-
210 targeting BDNF, miRNA-21 modulating microglia, and
miRNAs −27a and −132 modulating Tau would contribute to
enlightening what pathway triggers a neuron to transform into an
undifferentiated and immortal tumor cell or deteriorated dying
cells. It is also worth noticing that miRNA-10b does not express
in normal brain tissue (Gabriely et al., 2011), so it would represent
an attractive diagnostic approach.
Regarding NDDs, in addition to mutations found in
the pathognomic proteins, specific miRNAs expressions are
significantly altered during disease progression, proposing them
as contributing factors of these diseases (Figure 3 and Table 1),
despite the molecular and cellular functions of these miRNAs
are poorly studied.
GBM is a very aggressive cancer characterized by a very
low rate of patients’ 5-years survival. Part of the problem is
because the symptom’s appearance and the tumor detection are
often belated; consequently, the tumor reaches larger dimensions
than treatable. Also, the highly cellular plasticity that drives
these tumors with a massive spreading within brain parenchyma
and their heterogeneous microenvironment contributes to the
difficult scenario. Current therapy is ineffective, being the surgery
the most appropriate treatment; however, given its high degree
of invasiveness, the removal of the tumor is usually incomplete
and the tumor relapses. Although its early detection is critical,
there is not a currently available method. Therefore, deregulated
expression of specific miRNAs, some of them found regularly
loaded in EVs and associated with cancer progression, could
be used as biomarkers and therapy design. Indeed, some of
them, and also other entities in liquid biopsies such as cell-
free DNA, are currently being evaluated to provide accurate
and complementary information about the molecular or genetic
makeup of this heterogeneous tumor. However, the development
of new technology is required to advance in this aspect.
Further efforts should be done to better understand the
complexity of these pathologies; by deeply exploring the diversity
of deregulated miRNAs network and their potential association
with EVs. This is an important aspect to comprehend their
regulatory action, their roles in the major pathways, and to find
potential treatments. This review intends to provide the most
recent updates in the field to explore the potential nexus between
GBM and NDDs, by discussing the major pathophysiological
regulatory points, focusing on those deregulated miRNAs, mostly
associated with EVs. Therefore, we consider we have provided
a comprehensive insight into the molecular mechanisms, to
find common and opposite elements to be considered in
future research.
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